Physician profile
Andrea Cherry
NPI 1881277184
$3,014.44
in general payments reported to CMS, 2019-2025
30 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $530 · 2023: $1,088 · 2024: $788 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762 · Education: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.27 |
| Education | $583.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $394.16 | 2023-2025 | Padcev, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $225.57 | 2021-2023 | Opdivo |
| Sobi, INC | $212.73 | 2024-2025 | |
| Janssen Biotech, INC. | $153.00 | 2021-2024 | Rybrevant, Akeega, Balversa |
| Amgen INC. | $148.01 | 2022-2023 | Lumakras |
| Genzyme Corporation | $141.57 | 2021-2024 | |
| Incyte Corporation | $132.87 | 2023 | Jakafi |
| Puma Biotechnology, INC. | $128.48 | 2022 | |
| Genentech, INC. | $127.05 | 2023 | |
| Lilly USA, LLC | $125.13 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Stemline Therapeutics INC. | $121.18 | 2023 | Orserdu |
| Pharmacosmos Therapeutics INC. | $114.77 | 2024-2025 | Monoferric |
| Abbvie INC. | $108.27 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $91.37 | 2022-2023 | Imbruvica, Epkinly |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.11 | 2022-2024 | |
| Beigene USA, INC. | $86.23 | 2023 | Brukinsa |
| Pfizer INC. | $85.83 | 2022-2024 | |
| Boston Scientific Corporation | $76.64 | 2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $60.90 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Adc Therapeutics America, INC. | $48.01 | 2025 | |
| Genentech USA, INC. | $42.61 | 2025 | Phesgo, Polivy |
| Daiichi Sankyo INC. | $39.52 | 2022-2024 | Enhertu |
| Glaxosmithkline, LLC. | $34.53 | 2023-2025 | Ojjaara, Zejula |
| Acrotech Biopharma INC. | $34.18 | 2023-2025 | Beleodaq |
| Eisai INC. | $24.59 | 2024 | |
| Emd Serono, INC. | $21.81 | 2024 | |
| Sun Pharmaceutical Industries INC. | $19.57 | 2022 | |
| Celgene Corporation | $13.88 | 2023 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $10.92 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.